On May 9, 2026, the 2026 Distributors Conference of China National Accord Medicines Corporation Beijing Tiantan Biological Products Co., Ltd. (CNBG Tiantan Bio) was held in Chengdu, Sichuan Province. Dr. David Pan, the partner in charge of the compliance practice at Llinks, was invited to deliver a specialized compliance training session for the attendees.
With the theme "Compliance is Not a Cost, But the Core Competitiveness of a Brand," Dr. Pan systematically interpreted the substantial impact of the new judicial interpretations issued by the Supreme People's Court and the Supreme People's Procuratorate, which came into effect on May 1, 2026, on pharmaceutical marketing models. Through the analysis of real-world cases, he dissected criminal risks such as commercial bribery, fraudulent academic promotion, medical insurance fraud, and data non-compliance. Furthermore, he provided practical compliance tools, including a "Red, Yellow, and Green Light Behavioral Checklist," offering actionable advice on compliance empowerment, risk avoidance, and efficiency enhancement for the participating entities in this era of strict regulation. The training closely aligned with CNBG Tiantan Bio's cooperative initiative of "strictly adhering to the compliance bottom line," providing solid legal support for the collaborative development between the manufacturer and its distributors.
Llinks will continue to closely monitor legislative and regulatory dynamics with a professional and pragmatic approach, providing comprehensive compliance legal services for enterprises in the pharmaceutical and healthcare sectors to help them achieve steady and long-term success.
